Clinical Trial proves Efficacy and Safety of AstraZeneca Heart Drug Brilinta

March 16, 2015 12:55 PM

13 0

New anti-clotting drug Brilinta, developed by AstraZeneca, has produced promising results over its efficacy and safety in a clinical trial. Led by Brigham and Women’s Hospital and Harvard Medical School cardiologist Dr. Marc Sabatine, the study involved over 21,000 individuals in 31 countries. The drug was administered in all of them and survival rate after a heart attack within the last three years was 100% for all of them.

Sabatine said the benefits of the drug were found to be consistent in the individual components of heart health events and in all the major subgroups of patients.

Read more

To category page